REG - Haleon PLC - Transactions in Own Shares

HALEONAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260505:nRSE8862Ca&default-theme=true

RNS Number : 8862C  Haleon PLC  05 May 2026

 

Haleon plc: Aggregated information - transactions in own shares

 

5 May 2026: Haleon plc (the "Company" or "Haleon") today announces the
purchase of 12,171,987 ordinary shares of £0.01 each in the Company (the
"Shares") for cancellation under its share buyback programme announced on 12
March 2026.

 

                                                    London Stock Exchange  CBOE (UK)/BXE  CBOE (UK)/CXE  Aquis
 Date of purchase:                                  27 April 2026
 Number of Shares purchased:                        1,308,429              656,619        797,997        -
 Highest price paid per Share (p):                  353.3000               353.3000       353.3000       -
 Lowest price paid per Share (p):                   349.4000               349.4000       349.4000       -
 Volume weighted average price paid per Share (p):  350.8780               350.7867       350.8309       -
 Date of purchase:                                  28 April 2026
 Number of Shares purchased:                        556,329                371,197        472,474        -
 Highest price paid per Share (p):                  351.8000               351.8000       351.8000       -
 Lowest price paid per Share (p):                   348.5000               348.4000       348.5000       -
 Volume weighted average price paid per Share (p):  349.9766               349.9554       349.9275       -
 Date of purchase:                                  29 April 2026
 Number of Shares purchased:                        2,359,494              1,639,812      898,835        347,887
 Highest price paid per Share (p):                  359.6000               359.6000       360.0000       345.3000
 Lowest price paid per Share (p):                   333.8000               333.8000       334.5000       336.5000
 Volume weighted average price paid per Share (p):  338.4335               338.3904       339.5767       340.2554
 Date of purchase:                                  30 April 2026
 Number of Shares purchased:                        524,892                381,406        391,616        -
 Highest price paid per Share (p):                  342.9000               342.9000       342.8000       -
 Lowest price paid per Share (p):                   338.7000               338.7000       338.7000       -
 Volume weighted average price paid per Share (p):  340.6250               340.6757       340.6498       -
 Date of purchase:                                  1 May 2026
 Number of Shares purchased:                        639,274                249,799        575,927        -
 Highest price paid per Share (p):                  343.8000               343.1000       343.8000       -
 Lowest price paid per Share (p):                   336.0000               336.0000       336.0000       -
 Volume weighted average price paid per Share (p):  339.4396               339.5013       339.4039       -

 

Following the settlement of the above, the Company's registered share capital
is 8,890,467,595 ordinary shares of £0.01 each, of which 12,240,797 are
held as treasury shares. Therefore, the number of ordinary shares with voting
rights is 8,878,226,798 and this figure may be used by shareholders to
determine if they are required to notify their interest, or a change to their
interest, in Haleon under the FCA's Disclosure Guidance and Transparency
Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it
applies in the UK (the Market Abuse Regulation), a full breakdown of the
individual trades is available at the link below:

 

http://www.rns-pdf.londonstockexchange.com/rns/8862C_1-2026-5-1.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/8862C_1-2026-5-1.pdf)

 

This announcement does not constitute, or form part of, an offer or any
solicitation of an offer for securities in any jurisdiction.

 

This announcement and individual trade breakdown will also be available on the
Company's website at: www.haleon.com/investors
(http://www.haleon.com/investors) .

 

 Enquiries

 Investors                                                                       Media

 Jo Russell                              +44 7787 392441                         Zoë Bird                             +44 7736 746167
 Rakesh Patel                            +44 7552 484646                         Victoria Durman                      +44 7894 505730
 Email: investor-relations@haleon.com (mailto:investor-relations@haleon.com)     Email: corporate.media@haleon.com (mailto:corporate.media@haleon.com)

 

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better
everyday health. Our people, our brands, our research, our investment and our
innovation are aimed at improving the everyday health of consumers. Our
product portfolio spans six major categories - Oral Health, Vitamins, Minerals
and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and
Therapeutic Skin Health and Other. Our superior brands - such as Advil,
Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and
Voltaren - are trusted by more than one billion consumers and are recommended
by health professionals around the world.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSBLGDUBUGDGLB



            Copyright 2019 Regulatory News Service, all rights reserved